News - ARCH BIOPARTNERS RECEIVES PERMISSION FROM U.S. FDA June 27 (Reuters) - Arch Biopartners Inc:
* ARCH BIOPARTNERS RECEIVES PERMISSION FROM U.S. FDA TO PROCEED WITH PHASE II ACUTE KIDNEY INJURY TRIAL
* ARCH BIOPARTNERS INC - CS-AKI TRIAL HAS PLANS TO RECRUIT UP TO 240 PATIENTS
* ARCH BIOPARTNERS INC - PATIENT RECRUITMENT FOR CS-AKI TRIAL IS EXPECTED TO BEGIN IN FALL OF 2023